EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non‐small‐cell lung cancer

Yong Zhang, Xiang-Xiang Chen, Ruo Chen, Ling Li, Qing Ju, Dan Qiu, Yuan Wang, Peng-Yu Jing, Ning Chang, Min Wang, Jian Zhang, Zhi-Nan Chen und 1 weitere

Clinical and Translational Medicine · 2025-01 · 15 (1)

DOI: 10.1002/ctm2.70170 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 10.01.2025. Verfasst von Yong Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors, Dysbiosis, Lung Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Young Elite Scientist Sponsorship Program by China Association for Science and Technology, Clinical Booster Project of Fourth Military Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gut microbiome on predicting clinical responses to immune checkpoint inhibitors (ICIs) has been discussed in detail for decades, while microecological features of the lower respiratory tract within advanced non‐small‐cell lung cancer (NSCLC) are still relatively vague.

Methods

During this study, 26 bronchoalveolar lavage fluids (BALF) from advanced NSCLC participants who received immune checkpoint inhibitor monotherapy were performed 16S rRNA sequencing and untargeted metabolome sequencing to identify differentially abundant microbes and metabolic characteristics. Additionally, inflammatory cytokines and chemokines were also launched in paired BALF and serum samples by immunoassays to uncover their underlying correlations. The omics data were separately analyzed and integrated by using multiple correlation coefficients. Multiplex immunohistochemical staining was then used to assess the immune cell infiltration after immune checkpoint blockade therapy.

Results

Lower respiratory tract microbiome diversity favoured preferred responses to ICIs. Microbial markers demonstrated microbial diversity overweight a single strain in favoured response to ICI therapy, where Bacillus matters. Sphingomonas and Sediminibacterium were liable to remodulate lipid and essential amino acid degradations to embrace progression after immunotherapies. Microbiome‐derived metabolites reshaped the immune microenvironment in the lower respiratory tract by releasing inflammatory cytokines and chemokines, which was partially achieved by metabolite‐mediated tumoral inflammatory products and reduction of CD8 + effective T cells and M1 phenotypes macrophages in malignant lesions.

Conclusions

This study provided a microecological landscape of the lower respiratory tract with advanced NSCLC to ICI interventions and presented a multidimensional perspective with favoured outcomes that may improve the predictive capacity of the localized microbiome in clinical practices. Highlights Alterations of the lower respiratory tract microbiome indicate different clinical responses to ICB within advanced NSCLC. Reduced microbial diversity of lower respiratory tracts impairs anti‐tumoral performances. Microbe‐derived metabolites perform as a dominant regulator to remodify the microecological environment in lower respiratory tracts. Multi‐omics sequencings of the lower respiratory tract possess the potential to predict the long‐term clinical responses to ICB among advanced NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsDysbiosisLung NeoplasmsHumansFemaleMaleMiddle AgedAgedBronchoalveolar Lavage FluidMicrobiota

Stichwörter der Autor:innen

advanced non‐small‐cell lung cancerclinical outcomesimmune checkpoint blockade therapylower respiratory tract microbiomemulti‐omics analysis

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Cell Biology, National Translational Science Center for Molecular Medicine, Fourth Military Medical University, Xi'an, China.
  • State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Xi'an, China.
  • Department of Pulmonary and Critical Care of Medicine, The First Affiliated Hospital of Fourth Military Medical University, Xi'an, China.
  • Department of Microbiology, School of Basic Medicine, Fourth Military Medical University, Xi'an, China.
  • Department of Thoracic Surgery, The Second Affiliated Hospital of Fourth Military Medical University, Xi'an, China.

ORCID-Profile: Ke Wang

Förderung

  • National Natural Science Foundation of China
  • Young Elite Scientist Sponsorship Program by China Association for Science and Technology
  • Clinical Booster Project of Fourth Military Medical University

Zitieren

APA

Zhang, Y., Chen, X. X., Chen, R., Li, L., Ju, Q., Qiu, D., Wang, Y., Jing, P. Y., Chang, N., Wang, M., Zhang, J., Chen, Z. N., & Wang, K. (2025). Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non‐small‐cell lung cancer. Clinical and Translational Medicine, 15(1). https://doi.org/10.1002/ctm2.70170

Vancouver

Zhang Y, Chen XX, Chen R, Li L, Ju Q, Qiu D, et al. Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non‐small‐cell lung cancer. Clinical and Translational Medicine. 2025;15(1). doi:10.1002/ctm2.70170

BibTeX
@article{Zhang2025,
  author = {Zhang, Yong and Chen, Xiang-Xiang and Chen, Ruo and Li, Ling and Ju, Qing and Qiu, Dan and Wang, Yuan and Jing, Peng-Yu and Chang, Ning and Wang, Min and Zhang, Jian and Chen, Zhi-Nan and Wang, Ke},
  title = {Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non‐small‐cell lung cancer},
  journal = {Clinical and Translational Medicine},
  year = {2025},
  volume = {15},
  number = {1},
  doi = {10.1002/ctm2.70170}
}
Kostenlos starten →